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Early full-term pregnancy is one of the most effective
natural protections against breast cancer. To investi-
gate this effect, we have characterized the globalgene expression and epigenetic profiles of multiple
cell types from normal breast tissue of nulliparous
and parous women and carriers of BRCA1 or
BRCA2 mutations. We found significant differences
in CD44+ progenitor cells, where the levels of manyCell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 117
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Parity-Related Changes in the Normal Breaststem cell-related genes and pathways, including the
cell-cycle regulator p27, are lower in parous women
without BRCA1/BRCA2 mutations. We also noted a
significant reduction in the frequency of CD44+p27+
cells in parous women and showed, using explant
cultures, that parity-related signaling pathways play
a role in regulating the number of p27+ cells and their
proliferation. Our results suggest that pathways con-
trolling p27+ mammary epithelial cells and the
numbers of these cells relate to breast cancer risk
and can be explored for cancer risk assessment
and prevention.
INTRODUCTION
A single full-term pregnancy in early adulthood decreases the
risk for estrogen receptor-positive (ER+) postmenopausal breast
cancer, the most common form of the disease (Colditz et al.,
2004). Age at first pregnancy is critical because the protective
effect decreases after the mid 20s, and women aged >35 at first
birth have increased risk for both ER+ and ER breast cancer.
Parity-associated risk is also influenced by germline variants.
For example, BRCA1 and BRCA2 (hereafter BRCA1/BRCA2)
mutation carriers do not experience the same risk reduction as
do women in the general population (Cullinane et al., 2005).
These epidemiological data suggest that pregnancy induces
long-lasting changes in the normal breast epithelium and that
its effects are distinct for ER+ and ER tumors.
The protective effect of pregnancy is also observed in animal
models and can be mimicked by hormonal factors (Ginger and
Rosen, 2003; Russo et al., 2005; Sivaraman and Medina,
2002). The cellular and molecular mechanisms that underlie
pregnancy and hormone-induced refractoriness to tumorigen-
esis are largely undefined. Hypotheses proposed include induc-
tion of differentiation, decreased susceptibility to carcinogens,
reduction in cell proliferation and in stem cell number, and
altered systemic environment due to a decrease in circulating
growth hormone and other endocrine factors (Ginger and Rosen,
2003; Russo et al., 2005; Sivaraman and Medina, 2002).
Almost all studies investigating pregnancy-induced changes
and the breast cancer-preventative effects of pregnancy have
been conducted in rodents andmostly focused on themammary
gland. Global gene expression profiling ofmammary glands from
virgin and parous rats identified changes in TGF-b and IGF
signaling and in the expression of extracellular matrix proteins
(Blakely et al., 2006; D’Cruz et al., 2002). Related studies in
humans also identified consistent differences in gene expression
profiles between nulliparous and parous women (Asztalos et al.,
2010; Belitskaya-Le´vy et al., 2011; Russo et al., 2008, 2012).
Nevertheless, because these studies have usedmammary gland
or organoids, which are composed of multiple cell types, the
cellular origin of these gene expression differences remains
unknown.
Emerging data indicate that mammary epithelial progenitor or
stem cells are the normal cell of origin of breast carcinomas, and
breast cancer risk factors may alter the number and/or proper-
ties of these cells (Visvader, 2011). Studies assessing changes118 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.in mammary epithelial stem cells following pregnancy have
been conducted only in mice and so far have been inconclusive
(Asselin-Labat et al., 2010; Britt et al., 2009; Siwko et al., 2008).
Thus, the effect of pregnancy on the number and functional
properties of murine mammary epithelial progenitors remains
elusive and has not yet been analyzed in humans.
Here, we describe the detailed molecular characterization of
luminal and myoepithelial cells, lineage-negative (lin) cells
with progenitor features, and stromal fibroblasts from nulliparous
and parous women including BRCA1/BRCA2 mutation carriers,
the identification of cell-type-specific differences related to
parity, functional validation of hormonal factors and selected
parity-related pathways on the proliferation of mammary epithe-
lial cells, and the relevance of these to breast cancer risk.
RESULTS
Parity-Related Differences in Gene Expression Patterns
To investigate parity-associated differences in the normal human
breast, first, we defined three distinct mammary epithelial cell
populations by FACS (fluorescence-activated cell sorting) for
cell surface markers previously associated with luminal (CD24),
myoepithelial (CD10), and progenitor features (lin/CD44+)
(Bloushtain-Qimron et al., 2008; Mani et al., 2008; Shipitsin
et al., 2007). Cells stained for these markers showed minimal
overlap both in nulliparous and parous tissues, with CD24+ and
CD44+ fractions being especially distinct (Figures S1A and S1B
available online). The fraction of CD44+ cells was slightly higher
in parous compared to nulliparous samples, likely due to the
more-developed lobulo-alveolar structures in parous women
(Russo et al., 2001) that appear to containmanyCD44+ cells (Fig-
ures S1B and S1C). We also performed multicolor immunofluo-
rescence analyses for these three cell surface markers and
genes specific for luminal (e.g., GATA3) and myoepithelial (e.g.,
SMA) cells to further confirm the identity of the cells (Figure S1D).
To investigate parity-related differences in gene expression
profiles, we analyzed immunomagnetic bead-purified (Bloush-
tain-Qimron et al., 2008; Shipitsin et al., 2007) CD24+, CD10+,
and CD44+ cells (captured sequentially in this order; thus,
CD44+ fraction is CD24CD10CD44+, but the CD24+ fraction
may contain CD24+CD44+ cells) and fibroblast-enriched stroma
from multiple nulliparous and parous women using SAGE-seq
(serial analysis of gene expression applied to high-throughput
sequencing) (Maruyama et al., 2012). To minimize variability
unrelated to parity status, women were closely matched for
age, number of pregnancies, age at first and time since last
pregnancy, and ethnicity (Table S1). The expression of known
cell-type-specific genes was consistently observed in each cell
type from nulliparous and parous samples based on SAGE-seq
confirming the purity and identity of the cells (Figure S2A).
Comparison of each cell type between nulliparous and parous
samples revealed the most pronounced differences in CD44+
cells, where the numbers of significantly (p < 0.05) differentially
expressed genes and the fold differences were the largest
(Figure 1A; Table S2). The degrees of differences were smaller
and similar in CD10+ and CD24+ cells, whereas stromal fibro-
blasts had the fewest differentially expressed genes (Table S2).
Further examination using principal component analysis (PCA)
confirmed that CD24+ and CD10+ cells and fibroblasts from
Figure 1. Cell-type-Specific Differences in Gene Expression According to Parity and BRCA1/BRCA2 Mutation Status
(A) Genome-wide view of genes differentially expressed between nulliparous (N) and parous (P) samples in the four cell types analyzed. Each dot represents a
gene. Fold differences between averaged N and P samples and their corresponding p values are plotted on the y and x axis, respectively. Green vertical lines and
numbers indicate p = 0.05 and genes differentially expressed at p < 0.05, respectively.
(B) 3D projection of the gene expression data onto the first three principal components. Each ball is a different sample; cell type and parity are indicated.
(C) Bar plot of the paired Euclidean distance for each of the four cell types. p value indicates the significance of difference (Kolmogorov-Smirnov test) between
parous and nulliparous groups in CD44+ and other cell types.
(D) Hierarchical clustering of Norwegian cohort based on Pearson correlation using genes differentially expressed in CD44+ cells.
(E) SELs for the samples corresponding to (D).
(F) Hierarchical clustering of CD44+ cells from nulliparous and parous control women and parous BRCA1/BRCA2 mutation carriers with the exception of one
BRCA2 sample (N152, highlighted in orange) that was nulliparous.
(G) Relative frequency of CD44+, CD24+, and CD10+ cells. Ten samples were analyzed from each of the indicated groups. Each dot represents an individual
sample. Error bars represent mean ± SEM.
Boxes in (C) and (E) correspond to the first (Q1) to the third (Q3) quartile, the line within the box is the median, and whiskers are from Q1 1.53 IQR (interquartile
range: = Q3  Q1) to Q3 + 1.5 3 IQR. See also Figures S1 and S2, and Tables S1, S2, and S3.
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Parity-Related Changes in the Normal Breastnulliparous and parous women were highly similar, whereas
CD44+ cells formed very distinct nulliparous and parous clusters
(Figure 1B). In line with this, CD44+ cells demonstrated the
largest distance in gene expression patterns between nullipa-
rous and parous samples (Figure 1C).
To validate our findings in an independent data set, we
analyzed the levels of our differentially expressed genes in a Nor-
wegian cohort (Haakensen et al., 2011a, 2011b) matched to our
samples for age (<40) and parity (P2). Clustering analysis usingour differentially expressed gene sets divided these samples
into a distinct nulliparous and a mixed parous/nulliparous group
(Figure 1D). Using genes differentially expressed in all four cell
types combined or only in CD44+ cells gave identical results.
Interestingly, nulliparous samples that formed a distinct cluster
(nulliparous B) or were closer to parous cases (nulliparous A) dis-
played significant differences in serum estradiol levels (SELs)
with samples more similar to parous cases having low SELs (Fig-
ure 1E). Because SEL and breast epithelial cell proliferation areCell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 119
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Parity-Related Changes in the Normal Breasthigher in the luteal phase of the menstrual cycle, our findings
imply that cells from nulliparous and parous women may be
more distinct in luteal phase.
The expression of selected genes was validated in additional
samples by quantitative RT-PCR (qRT-PCR) using CD44+ cells
from multiple nulliparous and parous cases to confirm SAGE-
seq data (Figure S2B). Based on these findings in gene expres-
sion profiles, we focused our follow-up studies on CD44+ and
CD24+ cells.
Lack of Parity-Associated Differences in BRCA1/BRCA2
Mutation Carriers
To strengthen our hypothesis that the parity-associated differ-
ences we detected in CD44+ cells might be related to the risk
for breast cancer, we analyzed the gene expression profiles of
CD44+ cells fromparousBRCA1/BRCA2mutation carriers (Table
S3), whose risk is not decreased by parity (Cullinane et al., 2005).
CD44+ cells from parous BRCA1/BRCA2mutation carriers clus-
tered with CD44+ cells from nulliparous controls (Figure 1F), sug-
gesting that parity-associated changes observed in non-BRCA1/
BRCA2 carriers may not occur in these high-risk women.
To determine if the lack of parity-associated changes in CD44+
cells from BRCA1/BRCA2 women is due to differences in the
distribution of cell populations, we performed FACS analysis of
multiple tissue samples from BRCA1/BRCA2 and noncarrier
women. The relative frequency of CD44+ was slightly higher in
parous compared to nulliparous samples, which was associated
with a slight decrease in CD24+ cells, whereas the relative fre-
quency of CD10+ cells was about the same in all groups (Fig-
ure 1G). The increase in ratio of CD44+-to-CD24+ cells in parous
samples could potentially be due to the increased number of
lobulo-alveolar structures observed in parous women (Fig-
ure S1B) (Russo et al., 2001) or due to the loss of CD24+ cells
during involution.
Biological Pathways and Networks Affected by
Parity-Related Gene Expression Changes
Because the ultimate goal of our study is to identify targets
for chemoprevention that would mimic the cancer-protective
effects of parity, we investigatedwhich signaling pathwaysmight
be affected by parity-related molecular changes. Because early
pregnancy specifically decreases the risk for ER+ breast tumors,
we first explored our differentially expressed gene lists in CD44+
cells for candidate mediators of this effect. We found several
genes that may change cellular response to steroid hormones
by altering metabolism (e.g., HSD17B11) or by modulating
nuclear receptors (e.g., NCOR1) (Table S2). Androgen receptor
(AR) and one of its key targets PSA (KLK3) were highly expressed
in nulliparous CD44+ cells, implying active androgen signaling
that is decreased by parity. Among genes highly expressed in
parous CD44+ cells were a number of known tumor suppressors,
includingCASP8 (Cox et al., 2007),SCRIB (Humbert et al., 2008),
and DNA repair genes (e.g., PRKDC).
To determine overall activation of specific biological functions
due to parity, we performed pathway enrichment, network, and
protein interactome analyses using the MetaCore platform
(Nikolsky et al., 2009). We found that parity has similar global
effects on three of the four cell types analyzed because pathways
built on expression patterns in CD10+ and CD44+ cells and120 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.stroma cluster together for parous and nulliparous states (Fig-
ure 2A). The most significant pathways highly active in parous
samples in all three cell types included apoptosis, survival, and
immune response, whereas stem cells and development-related
pathways were enriched only in CD44+ cells from nulliparous
women (Figure 2B; Table S4). Pathways highly active in parous
stromawere enriched in fatty acidmetabolism and adipocyte dif-
ferentiation, consistent with adipose tissue development and a
decrease in breast density following pregnancy (Boyd et al.,
2009). The functional categories of genes affected by parity
were similar in all four cell types with receptors and enzymes
representing the most enriched groups (Figure 2C; Table S5).
We focused our further analysis on CD44+ cells that showed
the most pronounced differences between parous and nullipa-
rous states. Pathways highly active in nulliparous samples are
related to major developmental and tumorigenic pathways
including cytoskeleton remodeling, DNA methylation, and WNT
signaling, whereas pathways more active in parous samples
include PI3K/AKT signaling and apoptosis (Table S4). Impor-
tantly, the highest-scored pathway for high-in nulliparous genes
is four orders of magnitude more statistically significant than
those for high-in-parous genes, suggesting that downregulation
of protumorigenic developmental pathways is a prominent
feature of CD44+ cells from parous women. Interactome analysis
also demonstrated a much larger number of overconnected pro-
teins in nulliparous than in parous state in all four cell types, but
particularly in CD44+ cells (Figure 2C). Because the relative num-
ber of interactions (connectivity) is directly related to the func-
tional activity of a data set (Nikolsky et al., 2008), these results
suggest that parous cells are substantially less active than nullip-
arous ones. The most overconnected (and overexpressed) tran-
scription factor (TF) in nulliparous CD44+ cells is SCMH-1, a
component of PRC1, which is required for the repression of
many genes during development and for the maintenance of
hematopoietic stem cells (Ohtsubo et al., 2008). The causal
network assembled from the top-scored pathways and over-
connected genes high in nulliparous CD44+ cells included a
number of tumorigenic pathways. The network’s key ‘‘triggers’’
(i.e., secreted ligands) comprise IL-6, VEGFA, PDGF-B, CCL-2,
NOTCH, and BMP4, signaling through major hubs such as
PI3K, GSKb, b-catenin, RhoA/Rac1, MEK3, and MEK4. The
network activated in CD44+ cells from parous women featured
IL-10, IL-23, TGF-b2 as ligands, b3 adrenergic receptor, and
TFs STAT1, STAT4, STAT5, and NF-kB.
We also explored pathways significantly different in CD44+
cells from control parous and BRCA1/BRCA2mutation carriers.
Very few pathways were common between cells from BRCA1/
BRCA2 mutation carriers, implying that although both are
distinct compared to control parous women, they are also
different from one another. Several of the top-scoring pathways
in cells fromBRCA1mutation carriers relate to DNA damage, cell
cycle, and apoptosis, whereas in cells of BRCA2 mutation car-
riers, many significantly high-scoring pathways are involved in
stem cells such as WNT, Slit-Robo, and IGF signaling (Table S4).
Conservation of Parity-Associated Pathways across
Species
Because pregnancy-induced protection against mammary
tumors is also observed in rodents, we investigated whether
Figure 2. Signaling Pathways Affected by Parity-Related Differences in Gene Expression Patterns
(A) Dendrogram depicting hierarchical clustering of signaling pathways significantly high in parous or nulliparous samples in any of the four cell types analyzed.
(B) Heatmap depicting unsupervised clustering of signaling pathways significantly down- or upregulated in parous compared to nulliparous samples in any of the
four cell types analyzed. Color scale indicates log p value of enrichment. Orange rectangles highlight cell-type-specific or common altered pathways.
(C) Genes differentially expressed between nulliparous and parous samples in each of the four cell types were analyzed for relative enrichment with the indicated
protein classes (lower panel) and for relative connectivity (upper panel). y axes indicatelog p values for enrichment with the listed protein classes or the number
of overconnected objects.
(D) Venn diagram depicting the number of unique and common pathways high in CD44+ cells from nulliparous women and in mammary glands of virgin rats,
respectively.
(E) List of top common pathways downregulated in CD44+ cells andmammary glands from parous women and rats, respectively. Name of pathways and p values
of enrichment are indicated.
See also Tables S4 and S5.
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Parity-Related Changes in the Normal Breastpathways altered by parity are conserved across species. We
compared pathways in CD44+ cells to those generated based
on genes differentially expressed between virgin and parous
rats (Blakely et al., 2006).We found a significant overlap between
pathways highly active in nulliparous and virgin samples, with
top-ranked pathways, including cytoskeleton remodeling and
cell adhesion, known to be highly relevant in stem cells (Figures
2D and 2E). A network built of the common pathways included a
complete NOTCH pathway, IGF, EGF, CD44, CD9, and ITGB1 as
triggers (i.e., ligands and receptors), c-Src, PKC, and FAK asma-
jor signaling kinases, and c-Jun, p53, SNAIL1, and LEF as TFs.
Thus, pregnancy appears to induce similar alterations in the
mammary gland regardless of species.
Cell-type-Specific Epigenetic Patterns Related to Parity
and Their Functional Relevance
Reduction of breast cancer risk in postmenopausal women
conferred by full-term pregnancy in early adulthood implies theinduction of long-lasting changes such as alterations in epige-
netic patterns. To investigate this hypothesis, we analyzed the
comprehensive DNAmethylation and histone H3 lysine 27 trime-
thylation (K27) profiles of CD24+ and CD44+ cells from nullipa-
rous and parous women using MSDK-seq (methylation-specific
digital karyotyping applied to high-throughput sequencing) (Hu
et al., 2005) and ChIP-seq (chromatin immunoprecipitation
applied to high-throughput sequencing) (Maruyama et al.,
2011), respectively. Comparison of MSDK-seq libraries of nullip-
arous and parous samples within each cell type showed a higher
number of significantly (p < 0.05) differentially methylated
regions (DMRs) in CD44+ cells. In both cell types, more DMRs
were hypermethylated in nulliparous than in parous cells (Fig-
ure 3A; Table S6). The differences in methylation of selected
genes were validated in additional samples by quantitative
methylation-specific PCR (qMSP) using CD44+ cells from multi-
ple nulliparous and parous cases to confirm MSDK-seq data
(Figure S3A).Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 121
Figure 3. Epigenetic Differences between Nulliparous and Parous Tissues
(A) Genome-wide view of differentially methylated genes in CD24+ and CD44+ cells between nulliparous and parous samples. All MSDK sites are plotted on the
x axis in the order of p values of the difference between nulliparous and parous samples in CD44+ or CD24+ cells. Log ratios of averaged MSDK counts in three
N and three P samples are plotted on the y axis. Green vertical lines indicate p = 0.01, and the number of significant DMRs (p < 0.01) is shown.
(B) Pathways enriched with genes in CD44+ cells with the indicated difference in DNA methylation between nulliparous and parous women.
(C) Genes with promoter and gene body DMRs in CD44+ cells from nulliparous and parous samples were analyzed for relative enrichment with the indicated
protein classes and for relative connectivity. y Axes indicatelog p values for enrichment with the listed protein classes or the number of overconnected objects.
(D) Pie charts depicting the relative percentage (%) of genes in different functional categories with the indicated gene expression and DNAmethylation pattern in
CD44+ cells from nulliparous and parous women.
(E) Scatterplot for MSDK-seq and SAGE-seq data to depict correlations between differential promoter methylation and differential gene expression for TFs. Each
point represents a gene with a MSDK-seq site in a certain region (promoter, 5 to +2 kb from TSS; gene body, +2 kb from TSS to the end of gene), and
log10 p value is plotted for difference of DNA methylation (x axis) and expression (y axis) between parous and nulliparous samples. If a MSDK site is hyper-
methylated or a gene is higher expressed in parous, 1 is multiplied by log10 p value, providing positive values. MSDK-seq sites that are significantly (p < 0.05)
hypo- or hypermethylated in parous or nulliparous samples are highlighted in blue.
See also Figure S3, and Tables S5, S6, and S7.
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alterations, we analyzed pathways enriched by genes associ-
ated with gene body or promoter DMRs in CD44+ cells from
nulliparous and parous samples and found very little overlap
among the four distinct categories (Figure 3B). Promoter hyper-
methylation in parous CD44+ cells involved stem cell (e.g., H3K9
demethylase, FGF2, BMP, EGFR, pluripotency) and apoptosis122 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.and survival pathways, whereas promoter hypermethylation in
nulliparous CD44+ cells involved stem cell (e.g., TGF-b/SMAD,
H3K4 demethylase) pathways, cell cycle, and nucleotide
metabolism.
The fraction of TFs among differentially methylated genes is 2-
to 3-fold higher than expected and than observed for differen-
tially expressed genes, implying that promoter methylation is a
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Parity-Related Changes in the Normal Breastpreferred control mechanism of their expression (Figures 3C and
3D). Similar to the expression data, DMRs in nulliparous samples
had higher numbers of overconnected objects than in parous
ones. Gene body DMRs in nulliparous CD44+ cells had the high-
est number of overconnected objects, and TFs represented a
significant fraction of overconnected objects in promoter hyper-
methylated DMRs in nulliparous CD44+ cells (Figure 3C).
We also analyzed associations between differential gene
expression and presence of DMRs in CD44+ and CD24+cells.
However, we found no significant correlation at the global scale
(data not shown), potentially due to the complex relationship
between DNA methylation and transcription because DNA
methylation can have both positive and negative effects on
gene expression, depending on the location relative to the tran-
scription start site (Jones, 1999). Even so, the expression of
several TFs with key roles in stem cells (e.g., HES7, STAT1)
was correlated with the degree of promoter or gene body DNA
methylation (Figure 3E). Our results correlate with recent findings
that most differentially expressed genes in multiple tissue types
do not show significant differences in DNA methylation except
for TFs (Bock et al., 2012).
Because of the importance of TF networks in parity-associ-
ated epigenetic changes, we also explored the potential of
DMRs tomodulate the action of specific TFs relevant to develop-
ment and tumorigenesis by searching for enrichment of specific
TF binding sites (TFBSs) within nulliparous or parous-specific
DMRs using the ENCODE Regulation Supertrack (Birney et al.,
2007). Of the 144 documented TFs, 45 exhibited significant
(adjusted p < 0.05, Benjamini Hochberg corrected) enrichment
in the DMRs, and a number of these (e.g., TCF4, STAT3, and
CEBPB) were significantly differentially enriched between par-
ous and nulliparous DMRs (Figure S3B), implying that parity-
induced epigenetic changes can affect the availability of DNA
for specific factors and, therefore, may affect the etiology of
breast cancer.
Analysis of the H3K27me3 profiles of CD44+ or CD24+ cells
from nulliparous and parous samples did not detect significant
parity-related differences (Figure S3C; data not shown). How-
ever, high-in nulliparous genes in either cell type were never
K27 enriched, thereby implying the potential lack of regulation
by the PRC2 that establishes this histone mark (Table S7). Over-
all, it appears that pregnancy may have a more-pronounced
long-term effect on DNA methylation than on K27 patterns and
that parity-associated differences in DNAmethylation only affect
the expression of a limited number of TFs with key roles in devel-
opment and differentiation.
Persistent Parity-Related Decrease in p27+ Breast
Epithelial Cells
CDKN1B encoding for p27 was one of the most significantly
differentially expressed genes in CD44+ cells between nullipa-
rous and parous (high in nulliparous) and also control and
BRCA1/BRCA2 (high inBRCA1/BRCA2, Table S3) comparisons.
p27 is known to affect the number and proliferation of stem cells
and progenitors in several organs in mice (Cheng et al., 2000;
Oesterle et al., 2011). Thus, higher expression of p27 in CD44+
cells from nulliparous control and parous BRCA1/BRCA2 muta-
tion carrier women may indicate higher numbers of mammary
epithelial progenitors in these samples. To investigate thishypothesis, we performed immunofluorescence analysis for
p27 alone and in combination with CD24 and CD44 and Ki67
proliferation markers in both premenopausal and postmeno-
pausal tissues to confirm that the parity-related differences we
detected by global profiling of premenopausal women are main-
tained after menopause. We observed that p27 expression and
the number of p27+ cells were significantly lower in parous
compared to nulliparous samples from both pre- and postmen-
opausal women (Figures 4A–4C). The frequency of Ki67+ cells
was also significantly higher in nulliparous than parous cases,
and Ki67+ cells were rarely p27+ (Figures 4B and 4C).
To strengthen the link between the frequency of p27+ cells
and parity-related decrease in postmenopausal breast cancer
risk, we analyzed postmenopausal nulliparous and parous
women with or without breast cancer. Although cancer-free
nulliparous postmenopausal women exhibited a higher fraction
of p27+ cells than parous ones, the frequency of these cells was
the highest in parous postmenopausal women with breast can-
cer (Figure S4A). Interestingly, the difference in the frequency of
p27+ cells between control women and patients with breast
cancer was pronounced only in the postmenopausal parous
group (Figure S4A).
p27+ Cells Are Quiescent Hormone-Responsive Cells
with Progenitor Features
The mutually exclusive expression of Ki67 and p27 in breast
epithelial cells and their concordant decrease in parous women
implied that they might represent cycling and quiescent cells
with proliferative potential, respectively. Ovarian hormones are
the best-understood regulators of breast epithelial cell prolifera-
tion and also breast cancer risk (Brisken and O’Malley, 2010).
Our gene expression data indicated a decrease in AR signaling
in CD44+ cells from parous women (Table S2), and prior studies
implied a decrease in ER+ breast epithelial cells in parous
compared to nulliparous women (Taylor et al., 2009).
To explore the potential hormonal regulation of p27+ breast
epithelial cells, we analyzed the expression of p27, ER, and AR
in breast tissue samples from women of varying parity and hor-
monal status. These included nulliparous and parous women,
BRCA1/BRCA2 mutation carriers, women in early (8–10 weeks)
and late (22–26 weeks) stages of pregnancy, and premeno-
pausal women in the follicular and luteal phases of the menstrual
cycle or subject to ovarian hyperstimulation prior to oocyte
collection for in vitro fertilization. Multiple different regions of
the tissue samples were examined to account for tissue hetero-
geneity. We found that most p27+ cells were also ER+, and their
numbers were highest in BRCA1/BRCA2 mutation carriers and
the lowest in pregnant women and after ovarian hyperstimula-
tion, where both ovarian hormones and HCG (human chorionic
gonadotropin) levels are the highest (Figure 5A). The frequencies
of p27+, ER+, and p27+ER+ cells were also higher in nulliparous
compared to parous women and in follicular relative to luteal
phase of the menstrual cycle (Figure 5A). Overall, similar obser-
vations were made for AR, although the overlap between p27
and AR was less pronounced compared to that between p27
and ER (Figure 5B). The high fraction of AR+ cells in BRCA1
mutation carriers is particularly interesting because AR is
a genetic modifier of BRCA1-associated breast cancer risk
(Rebbeck et al., 1999).Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 123
Figure 4. Expression of p27 in Normal
Breast Tissue Samples
Representative examples of multicolor immuno-
fluorescence analyses of normal mammary
epithelium.
(A) Expression of p27, CD24, and CD44 in breast
tissue of premenopausal nulliparous (NP) and
parous (P) women. Graph shows the quantification
of p27-staining intensity in multiple samples.
(B and C) Immunofluorescence staining for p27
and Ki67 in breast tissue from premenopausal (B)
and postmenopausal (C) nulliparous and parous
women. Graphs show frequencies of p27+ and
Ki67+ cells in nulliparous and parous samples.
Arrowheads in (C) point to CD44+p27+ cells.
p values of differences between nulliparous and
parous groups are indicated. Error bars represent
median ± SEM. See also Figure S4.
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Parity-Related Changes in the Normal BreastTo further investigate the relationship between the numbers
of p27+ cells and ovarian hormone-induced breast epithelial
cell proliferation, we performed immunofluorescence analysis
for p27 and Ki67 in tissue samples with the highest differ-
ences in hormone levels. Correlating with prior data from
Chung et al. (2012) and Going et al. (1988), the frequency of
Ki67+ cells was the highest in the luteal phase of the menstrual
cycle when both estrogen and progesterone levels are high
(Figure 5C). Samples from early pregnancy had a lower fraction
of Ki67+ cells, and the number of these cells was lowest in the
follicular phase. The frequency of p27+ cells displayed an
inverse correlation with Ki67+ cell frequency: it was the highest
in the follicular phase and lowest in oocyte donors (Figure 5C).
Interestingly, a low but detectable fraction of p27+ cells was
also Ki67+ in the luteal phase and early pregnancy, potentially124 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.marking proliferating progenitors in
early G1 phase of the cell cycle when
p27 and Ki67 might overlap. The differ-
ences in the frequency of p27+ and
Ki67+ cells between the follicular and
luteal phases were less significant in
parous compared to nulliparous women
in part due to the lower overall fractions
of these cells in parous cases (Fig-
ure S4A). These results suggest that a
subset of p27+ cells might represent
quiescent hormone-responsive progeni-
tors and that their frequency relates to
breast cancer risk.
Functional Validation of
Parity-Related Differences
in Signaling Pathways
Several signaling pathways that are less
active in CD44+ cells from parous
women were related to stem cells (Fig-
ure 2A). To investigate whether inhibition
of these pathways affects the number
of p27+ and proliferating cells, we incu-
bated normal breast tissues in a tissueexplant culture model with inhibitors or agonists of selected
pathways (e.g., EGFR, Hh, TGF-b, and Wnt) for 8–10 days.
We tested inhibitors of irrelevant pathways as controls. For
each case, we cultured three pieces of breast tissue taken
from different regions of the same breast, to minimize
variability due to tissue heterogeneity. We then assessed the
number of p27+ cells and cellular proliferation based on bromo-
deoxyuridine (BrdU) incorporation (S phase cells) and Ki67
(cycling cells).
We found that tissue architecture and cellular viability were
maintained, and p27+, Ki67+, and BrdU+ cells were detected
in all conditions (Figures 6A and 6B). The frequency of p27+ cells
decreased most markedly following TGF-b receptor and IGFR
inhibitor treatment (Figure 6C). Treatment with TGF-b receptor
inhibitor significantly (p < 0.05) increased, whereas inhibition
Figure 5. Hormonal Factors and the Expression of p27 in Normal Breast Tissues
(A) Representative double-immunofluorescence staining for p27 and ER in breast tissue from the indicated groups of women. Graphs show frequencies of p27+,
ER+, and p27+ER+ cells in each group of samples.
(B) Representative double-immunofluorescence staining for p27 and AR in breast tissue from premenopausal nulliparous and parous women, and in BRCA1
mutation carriers. Graph shows frequencies of p27+ and AR+ cells in each set of samples.
(C) Representative double-immunofluorescence staining for p27 and Ki67 in breast tissue from the indicated groups of women. Graphs show frequencies of p27+,
Ki67+, and p27+Ki67+ cells in each group of samples.
Asterisks (*) indicate significant (p% 0.05, t test or Fisher’s exact test) differences between groups of four to eight samples. Error bars represent mean ± SD. See
also Figure S4.
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Parity-Related Changes in the Normal Breastof cAMP, EGFR, Cox2, Hh, and IGFR signaling decreased
the number of BrdU+ cells, respectively. The fraction of Ki67+
cells was lower in all inhibitor-treated cultures, with EGFR andCox2 inhibition having the most pronounced effects (Fig-
ure 6C), whereas stimulation with Shh increased proliferation
(Figure S4B).Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 125
Figure 6. Modulation of p27+ Breast Epithelial Cells and Proliferation by Hormonal and Parity-Related Pathways
(A) Representative hematoxylin and eosin staining depicting morphology of breast tissue after 8 days in culture.
(B) Representative examples of multicolor immunofluorescence analyses of BrdU+, p27+, and Ki67+ cells in control and tissues treated with inhibitors of the
indicated pathways.
(C) Frequency of Ki67+, BrdU+, and p27+ cells in each of the indicated conditions.
(D and E) Representative images of immunofluorescence analysis of p27 and graph depicting the frequency of p27+ cells in tissue slices from three to four
independent cases treated with hormones mimicking the indicated physiologic levels in women.
Asterisks indicate significant (p% 0.05) differences. Error bars represent mean ± SD. See also Figure S4.
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Parity-Related Changes in the Normal BreastTo determine whether the number and proliferation of p27+
cells are regulated by estrogen signaling, we analyzed the frac-
tion of p27+ and Ki67+ cells in tissue slices treated with varying
concentrations of ovarian hormones or tamoxifen. To correlate
the tissue slice data with that observed under physiologic condi-
tions (Figure 5), we used estrogen, progesterone, prolactin, and
HCG hormone levels that mimic serum levels in the follicular or
luteal phases of the menstrual cycle or in midpregnancy. We
observed that the number of p27+ cells was high in sections
treated with concentrations of estrogen present in follicular
phase and also following tamoxifen treatment, whereas it
decreased in cultures incubated with luteal phase and preg-
nancy level hormones (Figures 6D and S4B). These data further126 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.support our hypothesis that a subset of p27+ cells is hormone-
responsive cells.
In search of a direct link between p27+ cells and the signaling
pathways analyzed, we confirmed that the selected pathways
were active in p27+ cells (Figure 7A) and that the compounds
effectively inhibited their activity in these cells (Figures 7B
and 7C). Most importantly, phospho-Smad2 (pSmad2), a key
mediator of TGF-b signaling, demonstrated a significant overlap
with p27 both in tissue slices (Figure 7A) and in uncultured
patient samples (Figure 7D). The frequency of p27+pSmad2+
cells also fluctuated according to hormone levels displaying
inverse correlation with mammary epithelial cell proliferation
during the menstrual cycle and pregnancy (Figures 7D and 4A).
Figure 7. Signaling Pathways Regulating p27+ Breast Epithelial Cells
(A) Representative examples of multicolor immunofluorescence analyses of pSMAD2, pEGFR, Axin2+, and p27 cells in control and tissues treated with inhibitors
of the indicated pathways.
(B) Quantitation of differences in the expression of markers reflecting pathway activity between control (C) and inhibitor-treated (I) tissues.
(C) RGB spectra demonstrating overlap between the expression of p27 and the indicated marker.
(D) Double-immunofluorescence staining for p27 and pSmad2 in breast tissues from three to four independent cases of the indicated women. Graphs show
frequencies of p27+, pSmad2+, and p27+pSmad2+ cells in each group of samples.
Error bars represent mean ± SD.
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Parity-Related Changes in the Normal BreastThese results indicate a key role for TGF-b signaling in mammary
epithelial cell quiescence state likely via p27 (Polyak et al., 1994).
However, alternative hypotheses such as SMAD2-independent
paracrine effects of TGF-b cannot be excluded. Thus, these
data suggest that the decreased frequency of p27+ and Ki67+
cells in parous women is a reflection of the decreased activity
of stem cell-related signaling pathways after pregnancy, identi-
fying these pathways as potential targets for cancer-preventive
interventions.
DISCUSSION
Our comprehensive data set covering multiple cell types in
normal human breast tissue from nulliparous and parous women
provides an information resource for future investigation of the
way in which parity contributes to a reduction in breast cancer
risk. From our analysis of the data, we found that parity has the
most pronounced effect on CD44+ cells enriched for cells with
luminal progenitor features. Most of the differences relate to
transcriptional repression and downregulation of genes and
pathways important for stem cell function including EGF, IGF,Hh, and TGF-b signaling. Correlating with our findings, high-
circulating IGF-1 levels have been associated with increased
risk for ER+ breast cancer (Key et al., 2010). Similarly, germline
polymorphism in members of the TGF-b signaling pathway influ-
ences breast cancer susceptibility (Scollen et al., 2011).
The gene expression profiles of CD44+ cells from parous
BRCA1/BRCA2 mutation carriers were more similar to nullipa-
rous than to parous noncarriers, implying that parity-related
changes may not occur or may be much less apparent in these
high-risk women. Our results are consistent with epidemiologic
data demonstrating that pregnancy does not decrease breast
cancer risk in BRCA1/BRCA2 mutation carriers or only does so
after multiple (four or more) pregnancies (Cullinane et al., 2005;
Poynter et al., 2010). Interestingly, despite their overall similarity,
CD44+ cells from BRCA1/BRCA2 mutation carriers also dis-
played significant differences. Pathways related to DNA damage
and repair were the highest ranked in BRCA1 cells, correlating
with BRCA1’s function (Roy et al., 2012). In contrast, top-scoring
pathways in BRCA2 cells are involved in stem cell function,
development, and differentiation. These results imply that
although germline mutations in both genes increase breastCell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc. 127
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Parity-Related Changes in the Normal Breastcancer risk, the underlying mechanisms are likely to be distinct,
which could also explain the differences in breast tumor sub-
types that develop in these high-risk women.
In contrast to the significant parity-related differences in gene
expression profiles, cells from nulliparous and parous women
showed much less-pronounced differences in the epigenetic
patterns we analyzed. With the exception of a subset of TFs,
for the majority of differentially expressed genes, differences in
transcript levels were not associated with differences in DNA
methylation or enrichment for H3K27me3 mark. Although these
findings could in part be due to the limitations of the technologies
employed, they are consistent with results of studies investi-
gating the epigenetic profiles of hematopoietic and skin stem,
progenitor, mature cells in mice (Bock et al., 2012), and our
preliminary data in the mouse mammary gland (S.C. and K.P.,
unpublished data).
One of the intriguing findings of our study is the high number of
p27+ cells in breast tissues of nulliparous women and BRCA1/
BRCA2 mutation carriers with high risk for breast cancer, which
seems paradoxical because CDKN1B/p27kip1 is a tumor sup-
pressor and cell-cycle inhibitor. However, p27 has been shown
to play an important role in stem and progenitor cells, best char-
acterized in the murine hematopoietic and nervous system,
where loss of p27 increases the number of transit amplifying
progenitors, but not that of stem cells (Cheng et al., 2000; Mitsu-
hashi et al., 2001; Oesterle et al., 2011). In contrast, the conse-
quences of p27 deficiency in the mouse mammary gland have
been controversial. The role of p27 in mouse breast epithelium
has been assessed based on mammary transplant assays (Mur-
aoka et al., 2001) due to infertility and hormonal defects of female
p27/Cdkn1b/ mice (Fero et al., 1996; Kiyokawa et al., 1996).
Using this approach, in one study, p27 deficiency was asso-
ciated with hypoplasia and impaired ductal branching and
lobulo-alveolar differentiation (Muraoka et al., 2001), a pheno-
type consistent with a putative role for p27 in regulating the
number and proliferation of mammary epithelial progenitors
(although this was not investigated). In contrast, another study
using the same strain of mice found increased cell proliferation
but no defects in ducto-alveolar branching and differentiation
(Davison et al., 2003).
Based on our data, we hypothesize that p27 regulates the pro-
liferation and pool size of hormone-responsive progenitors with
proliferative potential. Thus, the lower numbers of these p27+
cells in control parous women may contribute to their lower
breast cancer risk. High p27 and quiescence of these cells are
regulated by TGF-b signaling, as implied by the colocalization
of pSmad2 with p27 and the increase in BrdU incorporation
with a concomitant decrease in p27 following TGF-b receptor
inhibitor treatment. Correlating with the presumed importance
of TGF-b signaling and p27 in hormone-responsive luminal pro-
genitors, recent whole-genome sequencing studies detected
inactivating CDKN1B and TGF-b pathway mutations in luminal
breast tumors (Stephens et al., 2012).
The frequency of p27+ cells was high in control nulliparous
women and even higher in BRCA1/BRCA2 carriers even though
these different groups of women are predisposed to different
types of breast cancer. Nulliparous women have increased
risk for postmenopausal ER+ breast cancer (Colditz et al.,
2004), whereas BRCA1 mutation carriers most commonly have128 Cell Stem Cell 13, 117–130, July 3, 2013 ª2013 Elsevier Inc.ER basal-like tumors (Maxwell and Domchek, 2012). However,
luminal progenitors may serve as potential cell of origin of
BRCA1-associated breast cancer and other basal-like tumors
(Lim et al., 2009; Molyneux et al., 2010). Our data demonstrating
increased frequency of hormone-responsive p27+ cells in all
high-risk women support this hypothesis.
In addition to pregnancy itself, the duration of breast-feeding
also significantly impacts breast cancer risk, which is especially
pronounced for the triple-negative (i.e., ERPRHER2) subtype
(Shinde et al., 2010). Thus, because we did not have breast-
feeding information on the samples used for our study, further
investigation is required to determine whether the changes in
molecular profiles and p27+ cell frequencies in parous women
are due to pregnancy itself or are also influenced by length of
breast-feeding.
In summary, we here describe global differences in gene
expression patterns in human mammary epithelial cells related
to parity and identified p27+ cells with progenitor features as a
potential marker of breast cancer risk. The pathways we identi-
fied, especially TGF-b, might be exploited for breast cancer
prevention because their modulation could deplete p27+ pro-
genitors and decrease breast cancer risk. Analysis of large
cohorts with detailed risk factor data and long-term follow-up
would be required to conclusively determine the relationships
between the frequency of these p27+ cells, the activity of
parity-related signaling pathways, and breast cancer risk.
EXPERIMENTAL PROCEDURES
Tissue Samples, Cell Purification, and Genomic Profiling
Fresh normal breast tissue specimens were collected at Harvard-affiliated
hospitals, at Johns Hopkins University School ofMedicine, and Baylor-Charles
A. Sammons Cancer Center using institutional review board-approved proto-
cols. Each collaborator had their own protocol at their institution, and we had
one in DFCI for using these samples. For organ cultures, thin (1 mm) slices of
epithelium-enriched breast tissue were cultured for 8 days in 6-well plates with
coculture inserts in M87A medium (Garbe et al., 2009). Detailed protocols for
cell purification and the generation of SAGE-seq, MSDK-seq, and ChIP-seq
libraries are posted at http://polyaklab.dfci.harvard.edu/. Genomic data
were analyzed as described before (Kowalczyk et al., 2011; Maruyama
et al., 2011; Wu et al., 2010). Semiquantitative and qRT-PCR and qMSP
analyses were performed on cells purified from 15 to 20 samples of nulliparous
and parous breast tissue as previously reported (Hu et al., 2005). Details are
included in the Supplemental Information.
FACS, Immunofluorescence, and Immunohistochemical Analyses
Single-cell suspension of human breast epithelial cells was obtained essen-
tially as described by Shipitsin et al. (2007). Cells were stained with propidium
iodine, PE/Cy7-CD10 (BioLegend; Clone HI10a), APC-CD24 (BioLegend;
clone ML5), and Zenon Alexa 405-labeled CD44 (BD; Clone 515). Immunohis-
tochemical and immunofluorescence analyses were performed essentially as
described by Shipitsin et al. (2007); detailed protocols are included in Supple-
mental Information.
ACCESSION NUMBERS
The GEO accession number for the data reported in this paper is GSE32017.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.05.004.
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